Development of cladribine treatment in multiple sclerosis

Cladribine is a new type of drug with properties of selective lymphocyte suppression that appear to favorably alter the clinical course of progressive multiple sclerosis (MS). The history of the development of cladribine treatment in chronic progressive MS is discussed, and the application of cladri...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 1996-07, Vol.1 (6), p.343-347
Main Authors: Sipe, JC, Romine, JS, Koziol, JA, McMillan, R, Zyroff, J, Beutler, E
Format: Article
Language:English
Subjects:
Cladribine - adverse effects
Cladribine - therapeutic use
Cross-Over Studies
Disease Progression
Double-Blind Method
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Multiple Sclerosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cladribine is a new type of drug with properties of selective lymphocyte suppression that appear to favorably alter the clinical course of progressive multiple sclerosis (MS). The history of the development of cladribine treatment in chronic progressive MS is discussed, and the application of cladribine treatment to progressive multiple sclerosis in a double-blind, placebo crossover study is reviewed. Cladribine selectively targets both resting and dividing lymphocytes and may be able to destroy the activated lymphocytes that induce CNS demyelination, thus producing stabilization or improvement in chronic MS. Although the role of cladribine has not yet been fully defined, additional studies are underway to evaluate the efficacy and safety of cladribine in both progressive MS and relapsing-remitting MS.
ISSN:1352-4585
1477-0970
DOI:10.1177/135245859600100612